第二届湾区半导体产业生态博览会（简称：湾芯展2025）将于 10月15-17日 在 深圳会展中心（福田）1/2/9 号馆 盛大开幕！本届展会覆盖 60,000m 2 展览面积，聚焦半导体全产业链的高效整合，以晶圆制造为核心纽 带，全面展示从IC设计到封装测试的产业生态，携手来自全球 600余家 半导体优质企业，预计为 60,000+ 专 业观众带来贯穿半导体产业链的前沿技术成果和最新解决方案。 不一样的展会 承上启下 国际化水平跃升，双向赋能产业协同 本届湾芯展的国际展商数量同比增长超50% ，国际化水平实现跨越式提升。湾芯展的巨大国际吸引力，植根 于中国市场的广阔前景与展会自身的精准定位。对于国际企业而言，湾芯展不仅是展示其尖端技术、先进产品 和解决方案的绝佳舞台，更是深入了解中国本土应用需求、实现 "技术落地" 与 "市场拓展" 双重目标的重要 通道。 以晶圆制造为纽带,打通全产业链 湾芯展2025以晶圆制造为核心纽带，深度联动IC设计、先进封装、化合物半导体等关键环节，构建起半导体 全产业链的"生态展示圈"，涵盖EDA/IP、半导体设备、半导体材料、核心零部件、晶圆制造、封装测试等前 沿技术，以场景化方 ...

Key Takeaways MRK faces major headwinds as Keytruda, its top revenue driver, nears the loss of exclusivity in 2028.Gardasil sales are sliding in China and Japan, with further weakness projected in 2H 2025.MRK eyes $3B in savings by 2027 as new drug approvals look to offset upcoming headwinds.Merck (MRK) is likely to face several headwinds over the next few years that could impact its sales and profits, with the most significant being the upcoming loss of exclusivity for its blockbuster PD-L1 inhibitor, Keyt ...

PresentationTerence FlynnEquity Analyst Good afternoon, everybody. We're going to get started here. But I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. I'm very pleased to be hosting Merck this afternoon. From the company, we have Rob Davis, the company's Chairman and CEO; and Dr. Eliav Barr, who is the company's Head of Global Clinical Development and also CMO. Thank you both so much for joining us today this afternoon. Looking forward to chatting. Just quickly, for important disclosures, pleas ...

Merck & Co (NYSE:MRK) FY Conference September 08, 2025 02:35 PM ET Unknown Speakertextnumber_of_speakersparagraphs ...

2025-2031全球与中国可生物降解微球市场现场深度分析及投资前景预测报告 【全新修订】：2025年9月 【出版机构】：中智信投研究网 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 1 可生物降解微球市场概述 1.2.1 全球不同产品类型可生物降解微球销售额增长趋势2020 VS 2024 VS 2031 1.2.2 聚己内酯型 1.2.3 聚乙烯醇型 1.1 产品定义及统计范围 1.2 按照不同产品类型，可生物降解微球主要可以分为如下几个类别 1.2.4 聚乳酸型 1.2.5 聚羟基脂肪酸酯型 1.2.6 聚乙烯醇型 1.3 从不同应用，可生物降解微球主要包括如下几个方面 1.3.1 全球不同应用可生物降解微球销售额增长趋势2020 VS 2024 VS 2031 1.3.2 复合材料 1.3.3 医疗技术 1.3.4 油漆和涂料 1.3.5 化妆品和个人护理 1.4 可生物降解微球行业背景、发展历史、现状及趋势 1.4.1 可生物降解微球行业目前现状分析 1.4.2 可生物降解微球发展趋势 2 全球可生物降解微球总体规模 ...

Core Insights - The session features the Merck management team, highlighting their expertise and focus on the company's pipeline development [2]. Company Overview - Caroline Litchfield serves as the Executive Vice President and Chief Financial Officer of Merck, indicating a strong leadership presence [2]. - Eliav Barr, the Senior Vice President and Chief Medical Officer, is responsible for managing all pipeline development at Merck, showcasing the company's commitment to advancing its product offerings [2].

Bio-Rad Laboratories (BIO) FY 2025 Conference September 04, 2025 12:45 PM ET Company ParticipantsBrandon Couillard - Managing DirectorRoop Lakkaraju - Executive VP & CFONorman Schwartz - Chairman & CEOBrandon CouillardGood afternoon. Welcome to the Wells Fargo Healthcare Conference. Thanks for being here. I'm Brandon Couillard. I cover life science tools and diagnostics sector here at the firm.It's a real treat to have Bio Rad with us back at the conference this year. Joining me for this conversation to my ...

Financial Data and Key Metrics Changes - Merck is in a transformation phase with a diversified set of growth drivers, aiming for over $50 billion in revenues by the mid-2030s from its pipeline [3][4] - The company is launching 20 products, most of which have blockbuster potential [3][4] Business Line Data and Key Metrics Changes - KEYTRUDA continues to show strong growth with 42 approved indications in the U.S. across 18 tumor types, with expectations for continued growth from new indications [6][7] - The subcutaneous formulation of KEYTRUDA is anticipated to achieve 30% to 40% adoption within 18 to 24 months post-launch [9][11] Market Data and Key Metrics Changes - The company is well-positioned to manage the impact of tariffs and has a diverse supply chain footprint [41][42] - The impact of the Most Favored Nation (MFN) policy is expected to be manageable, as it only accounts for less than 10% of revenues [42][43] Company Strategy and Development Direction - Merck is focused on innovation and expanding its pipeline, with plans to increase R&D investments due to a strong pipeline of 80 Phase III clinical programs [51][52] - Business development remains a priority, with a focus on bringing in innovative science that addresses unmet medical needs [67][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the loss of exclusivity for KEYTRUDA and emphasized the importance of their pipeline in driving future growth [5][6] - The company is optimistic about the readouts from its oncology and HIV pipelines in the coming year [80][81] Other Important Information - The company is preparing for the launch of its oral PCSK9 inhibitor, which is expected to democratize access to this treatment [60][62] - Merck is also excited about its cancer vaccine program, focusing on early-stage cancers with potential curative opportunities [39][40] Q&A Session Summary Question: What are the growth avenues for KEYTRUDA? - Management expects continued growth from new indications, including early-stage lung cancer and women's cancers [7][8] Question: How will the adoption of the subcutaneous formulation of KEYTRUDA be affected? - Factors such as pricing, access, and the J code will influence adoption rates, with expectations of 30% to 40% adoption within 18 to 24 months [10][11] Question: What is the confidence level in the TROP-two ADC program? - Management expressed confidence based on early signals and extensive clinical trials, highlighting its unique properties and potential in maintenance settings [17][18] Question: How does Merck plan to address macroeconomic headwinds like tariffs? - The company has a diverse supply chain and is well-positioned to manage tariff impacts, focusing on innovation and product launches [41][42] Question: What is the outlook for Gardasil in China? - Gardasil is not expected to drive significant growth in China, with future growth anticipated from international markets and new product launches [69][70] Question: What are the expectations for the cancer vaccine program? - The program is focused on early-stage cancers, with positive readouts expected in the next couple of years [39][40]

Financial Data and Key Metrics Changes - The company is in a transformation phase with a diversified set of growth drivers, expecting over $50 billion in revenues by the mid-2030s from its pipeline [3][4][5] - The company is launching 20 products, most of which have blockbuster potential [3][4] Business Line Data and Key Metrics Changes - KEYTRUDA continues to show strong growth with 42 approved indications across 18 tumor types, with new indications expected to drive future growth [6][7][8] - The subcutaneous formulation of KEYTRUDA is anticipated to achieve 30% to 40% adoption within 18 to 24 months post-launch [9][11] - The company has 24 oncology assets in clinical trials, focusing on immune stimulation, chemotherapy improvements, and specific targeting agents [13][15] Market Data and Key Metrics Changes - The company is well-positioned to manage tariff impacts due to a diverse supply chain and manufacturing footprint [42][43] - The impact of the Most Favored Nation (MFN) policy is expected to be manageable, with less than 10% of revenues affected [43][44] Company Strategy and Development Direction - The company is focused on innovation and expanding its pipeline, with a commitment to reinvest $3 billion in annual cost savings into R&D [51][52] - Business development remains a priority, with a focus on bringing in innovative science that addresses unmet medical needs [66][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the loss of exclusivity for KEYTRUDA and emphasized the importance of new product launches [5][6] - The company is optimistic about the future, with expectations for positive readouts from its pipeline and successful product launches [78][79] Other Important Information - The company is excited about the potential of its oral PCSK9 inhibitor, which showed a 60% reduction in LDL cholesterol in Phase II trials [59][60] - The company is also exploring opportunities in the GLP-1 space, with an oral formulation expected to enter Phase I trials [62][64] Q&A Session Summary Question: What are the growth avenues for KEYTRUDA? - Management highlighted new indications in lung cancer and women's cancers as key growth opportunities [6][7] Question: How does the company plan to handle tariff impacts? - The company has a diverse supply chain and believes the impact of tariffs is manageable [42][43] Question: What is the strategy for the new PD-1 VEGF bispecifics? - The company is focusing on specific patient strata and therapeutic indications to differentiate from existing treatments [32][33] Question: How will the company approach pricing in light of MFN? - The company plans to price products based on the value they bring, ensuring broad access while being mindful of MFN implications [44][46] Question: What is the outlook for the cancer vaccine program? - Management is optimistic about the enthusiasm from investigators and the potential for early-stage cancer treatments [39][40] Question: How does the company view the future of Gardasil in China? - Gardasil is not expected to drive significant growth in China, with focus shifting to international markets [68][69]

Core Viewpoint - The U.S. stock market is expected to perform well for long-term investors, despite Warren Buffett's cautious stance on current market leadership [1] Group 1: Investment Strategies - Buffett suggests that investors uninterested in closely following markets may consider S&P 500 index funds for wealth compounding [2] - Investing in the S&P 500 allows investors to benefit from the overall U.S. economy and capture significant winners like Nvidia, which has generated over $4 trillion in market cap in three years [8] Group 2: Market Composition - Currently, 19.9% of the S&P 500's total market cap is concentrated in three stocks: Nvidia, Microsoft, and Apple [3] - The S&P 500 is not static; it has evolved significantly over the past 30 years, with the largest companies transitioning from ExxonMobil and Coca-Cola to tech giants like Apple and Microsoft [5][6] - By 2025, the largest eight companies in the S&P 500 will be growth-focused, with the "Ten Titans" comprising 38% of the index [7] Group 3: Berkshire Hathaway's Position - Berkshire Hathaway is holding a record amount of cash and has not repurchased its own stock for four consecutive quarters, indicating a cautious approach in the current market [10][11] - Despite Buffett's endorsement of index funds, Berkshire has not significantly increased its position in mega-cap growth stocks during recent market downturns [11] Group 4: Investor Considerations - Long-term investors with high-risk tolerance may find it reasonable to invest in index funds dominated by growth stocks, while those with lower risk tolerance might prefer dividend-paying value stocks to mitigate premium valuations [13]